WaveMan
WaveMan · Company
CYTK · Cytokinetics Inc
> Search tickers & screens ⌘K
LIVE
← All companies

CYTK Cytokinetics (CYTK) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001061983
Quote by TradingView
Congress · 1Form 144 · 6
Insider buyers, 180 days
0
Funds added, last quarter
328
13F, latest reported quarter
Conversions, 180 days
37
Codes C/M, not in net · $5.3M priced

What the filings say about CYTK

Insiders, 180 days
-$31.2M net sold
9 sellers · 32% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-29
Planned sales (Form 144), 90 days
$11.9M
6 notices

Cytokinetics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CYTOKINETICS INC insiders sold a net $31.2M of stock across 362 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Malik Fady Ibraham
EVP Research & Development
SELL
2026-10-20 SEC
3,500
$224.0K
-3.4%
Context
  • 110 earlier Form 4 trades (code P or S) here by this insider (110 sales), the last on Oct 6, 2026.
  • The trade is 2.3% of the 153,902 shares held after it.
  • 1 other insider sold within 30 days.
  • 328 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Research & Development Malik Fady Ibraham sold about $224.0K of CYTK under a 10b5-1 plan on Oct 20, 2026; 1 other insider sold within 30 days and 328 funds added in the latest 13F quarter.
Blum Robert I
President & CEO
SELL
2026-10-13 SECtraded 2026-10-12
7,500
$471.6K
-4.3%
Context
  • 114 earlier Form 4 trades (code P or S) here by this insider (114 sales), the last on Sep 28, 2026.
  • The trade is 2.7% of the 278,544 shares held after it.
  • 2 other insiders sold within 30 days.
  • 328 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Blum Robert I sold about $471.6K of CYTK under a 10b5-1 plan on Oct 12, 2026; 2 other insiders sold within 30 days and 328 funds added in the latest 13F quarter.
Malik Fady Ibraham
EVP Research & Development
SELL
2026-10-06 SEC
3,500
$214.8K
-0.6%
Context
  • 109 earlier Form 4 trades (code P or S) here by this insider (109 sales), the last on Sep 22, 2026.
  • The trade is 2.3% of the 153,902 shares held after it.
  • 2 other insiders sold within 30 days.
  • 328 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Research & Development Malik Fady Ibraham sold about $214.8K of CYTK under a 10b5-1 plan on Oct 6, 2026; 2 other insiders sold within 30 days and 328 funds added in the latest 13F quarter.
Blum Robert I
President & CEO
SELL
2026-09-28 SEC
7,500
$490.9K
-7.5%
Context
  • 113 earlier Form 4 trades (code P or S) here by this insider (113 sales), the last on Sep 15, 2026.
  • The trade is 2.7% of the 278,544 shares held after it.
  • 4 other insiders sold within 30 days.
  • 328 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Blum Robert I sold about $490.9K of CYTK under a 10b5-1 plan on Sep 28, 2026; 4 other insiders sold within 30 days and 328 funds added in the latest 13F quarter.
Malik Fady Ibraham
EVP Research & Development
SELL
2026-09-22 SEC
3,500
$239.0K
-7.7%
Context
  • 108 earlier Form 4 trades (code P or S) here by this insider (108 sales), the last on Sep 8, 2026.
  • The trade is 2.3% of the 153,902 shares held after it.
  • 4 other insiders sold within 30 days.
  • 328 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Research & Development Malik Fady Ibraham sold about $239.0K of CYTK under a 10b5-1 plan on Sep 22, 2026; 4 other insiders sold within 30 days and 328 funds added in the latest 13F quarter.
362 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 357 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$31.2M over 180 days
-$12.9M over 90 days
below 91% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
328 funds bought in last quarter
more than 96% of Pharma & Biotech
Revenue
+376.6% year over year
more than 92% of Pharma & Biotech
Margin
-891.6% net margin
below 84% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
14.0% of the float short (float per yahoo 2026-10-26) · 8.4 days to cover · settled 2026-09-30
more than 82% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 20Officer FADY MALIK filed to sell $1.0M by Oct 20 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 20EVP Research & Development Malik Fady Ibraham sold $438.9K under a 10b5-1 plan (2 trades, Oct 6 to Oct 20)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13Director ROBERT BLUM filed to sell $1.4M by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13President & CEO Blum Robert I sold $471.6K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.

Watch CYTK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+5.6%12M
+0%+17%+35%+52%2025-102025-122026-022026-042026-062026-082026-10 2026-09-15 · Blum Robert I sold $6.8M2025-12-05 · Callos Andrew sold $3.5M2026-06-24 · Lee Sung sold $3.2M2025-12-01 · Kaye Edward M. MD sold $1.9M2026-05-05 · Lee Sung sold $1.8M2026-05-05 · HENDERSON JOHN T sold $1.5M2026-03-17 · Blum Robert I sold $1.5M2025-12-22 · WIERENGA WENDELL sold $1.3M2026-07-01 · Callos Andrew sold $1.3M2026-07-30 · Callos Andrew sold $1.1M2026-06-01 · Callos Andrew sold $1.1M2026-05-01 · Callos Andrew sold $1.0M2026-04-30 · Callos Andrew sold $948.9K2026-02-05 · Callos Andrew sold $929.0K2026-03-05 · Callos Andrew sold $928.0K2026-01-05 · Callos Andrew sold $904.2K2026-05-05 · Callos Andrew sold $875.5K2026-03-17 · Blum Robert I sold $787.6K2026-08-31 · Callos Andrew sold $702.4K2026-03-05 · Callos Andrew sold $680.7K2026-07-01 · Blum Robert I sold $636.9K2026-07-13 · Blum Robert I sold $614.3K2026-07-27 · Blum Robert I sold $606.5K2026-05-14 · Blum Robert I sold $584.4K2026-05-27 · Blum Robert I sold $579.1K2026-08-10 · Blum Robert I sold $575.7K2025-12-02 · HENDERSON JOHN T sold $559.1K2026-09-14 · Blum Robert I sold $550.8K2026-06-15 · Blum Robert I sold $528.5K2026-08-31 · Blum Robert I sold $526.8K2026-04-01 · Blum Robert I sold $499.7K2026-04-15 · Callos Andrew sold $491.8K2026-09-28 · Blum Robert I sold $490.9K2026-04-15 · Blum Robert I sold $490.3K2026-03-09 · Blum Robert I sold $481.6K2026-03-17 · Malik Fady Ibraham sold $474.6K2026-10-12 · Blum Robert I sold $471.6K2026-04-29 · Blum Robert I sold $447.1K2026-06-01 · PARSHALL B LYNNE sold $370.4K2026-09-01 · PARSHALL B LYNNE sold $357.4K2026-03-17 · Callos Andrew sold $349.7K2025-11-11 · Kaye Edward M. MD sold $336.8K2026-10-20 · FADY MALIK filed to sell $1.0M2026-10-13 · ROBERT BLUM filed to sell $1.4M2026-09-15 · Robert I. Blum filed to sell $7.1M2026-09-11 · ROBERT LANDRY filed to sell $147.2K2026-09-01 · B LYNNE PARSHALL filed to sell $354.6K2026-07-30 · ANDREW CALLOS filed to sell $1.9M2026-07-07 · FADY MALIK filed to sell $2.1M2026-07-01 · ROBERT BLUM filed to sell $4.5M2026-06-29 · Sung Lee filed to sell $781.1K2026-06-26 · Sung Lee filed to sell $541.0K2026-06-24 · Sung Lee filed to sell $3.1M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CYTK: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
20,094,362 sh
$1.7B
WELLINGTON MANAGEMENT GROUP LLP
6,931,770 sh
$590.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
6,711,799 sh
$571.8M
STATE STREET CORP
6,494,233 sh
$553.2M
VANGUARD CAPITAL MANAGEMENT LLC
6,117,515 sh
$521.2M

Congress trades in CYTK

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Bought 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-06-30 · disclosed 2 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-10-09 · disclosed 40 days later
$1,001 - $15,000
Lisa McClain
Sold 2025-06-17 · disclosed 57 days later
$1,001 - $15,000
Lisa McClain
Bought 2025-06-11 · disclosed 63 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CYTK planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
FADY MALIK
Filed 2026-10-20
$1.0M
ROBERT BLUM
Filed 2026-10-13
$1.4M
Robert I. Blum
Filed 2026-09-15
$7.1M
ROBERT LANDRY
Filed 2026-09-11
$147.2K
B LYNNE PARSHALL
Filed 2026-09-01
$354.6K

CYTK mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
F/m Emerald Life Sciences Innovation ETF
$3.3M position · as of 2026-05-31
3.2%
Eventide Healthcare & Life Sciences Fund
$48.0M position · as of 2026-06-30
2.7%
Tema Heart & Health ETF
$1.3M position · as of 2026-05-31
2.5%
Invesco Dorsey Wright Healthcare Momentum ETF
$4.4M position · as of 2026-07-31
1.9%
iShares Health Innovation Active ETF
$200.5K position · as of 2026-07-31
1.8%
T. Rowe Price Health Care ETF
$388.8K position · as of 2026-06-30
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
16 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
5
Phase 1
0 active
2
Phase 2
1 active
7
Phase 3
2 active
2
Multi-phase
2 active
What changed recently
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamte
2026-10-14 · Completion moved 2028-03 → 2029-03
PHASE2,PHASE3
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults W
2026-09-23 · Completion moved 2026-08 → 2026-08-31
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mr. Blum
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$8.8M
$20.7M
$2.9M
+687%
+15%
2022
$8.5M
$8.7M
$2.3M
+332%
+11%
2021
$6.4M
$19.9M
$2.7M
+330%
+25%
2020
$5.1M
$11.0M
$1.8M
+96%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $31.2M sold by insiders over 180 days, 328 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $11.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CYTK financials

Revenue growth
+376.6%
XBRL, annual
Net margin
-891.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$67.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-1,321%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$580.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-2.02x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-56.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-49.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$8.5B
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-6.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$88.0M$18.5M$7.5M$94.6M
Operating income-$612.3M-$536.2M-$496.2M-$324.2M
Net income-$785.0M-$589.5M-$526.2M-$389.0M
EPS (diluted)-6.54-5.26-5.45-4.33
Operating cash flow-$510.0M-$395.9M-$414.3M-$299.5M
Cash$122.5M$94.9M$113.0M$65.6M
Long-term debt$246.4M$93.2M$58.4M$63.8M
SEC XBRL, fiscal years, as known on 2026-10-28

CYTK Stock Sonar score 6/7 axes

Find similar shapesCompare

CYTK ranks highest on growth (92nd percentile) and institutional and government (60th), and lowest on insider conviction (5th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
45
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-56.8% · 40 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-49.9% · 50 pct, sector of 576
Financial health
44
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-2.02x · 44 pct, sector of 371
Growth
92
Inputs
  • Revenue growth, YoY+376.6% · 92 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
5
Inputs
  • Net Form 4 buying (codes P and S), 180d-$20.2M · 10 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
60
Inputs
  • Funds adding, latest quarter328 · 96 pct, sector of 698
  • Congress net buyers, 365d1 · 60 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$120K · 24 pct, sector of 133
Risk and compliance
18
Inputs
  • Short interest, % of float+14.0% · 27 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+28.6% · 8 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CYTK filings, in plain words

Are Cytokinetics insiders buying or selling CYTK?

In the 180 days to 2026-10-28, Cytokinetics insiders were net sellers, a net $31.2M across purchases and sales reported on Form 4, by 9 sellers.

Have members of Congress traded CYTK?

Yes. In the year to 2026-10-28, 1 House member disclosed buying CYTK and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29.

Are there planned insider sales of CYTK?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $11.9M of stock; the latest, by FADY MALIK, was filed 2026-10-20.

Read the full summary

In the 180 days to 2026-10-28, Cytokinetics insiders were net sellers of CYTK, a net $31.2M across purchases and sales reported on Form 4 by 9 sellers. 32% of the 41 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying CYTK and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $11.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies